(Q35946036)

11 August 2017

The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism (English)

1 reference

11 August 2017

3

Carl Grunfeld

1 reference

11 August 2017

Grace A Lee

1

1 reference

PubMed ID

15538985

11 August 2017

Madhu N Rao

series ordinal

2

1 reference

11 August 2017

1 December 2004

1 reference

Current infectious disease reports

11 August 2017

1 reference

11 August 2017

6

1 reference

11 August 2017

6

1 reference

11 August 2017

471-482

1 reference

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

11 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11908-004-0067-5

Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-004-0067-5

Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-004-0067-5

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-004-0067-5

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-004-0067-5

Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-004-0067-5

Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-004-0067-5

Alterations in lipid kinetics in men with HIV-dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-004-0067-5

Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-004-0067-5

Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-004-0067-5

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-004-0067-5

Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome

21 January 2018

1 reference

12 December 2020

A Comparison of the Effects of Nevirapine and Nelfinavir on Metabolism and Body Habitus in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Controlled Study

1 reference

12 December 2020

Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices

1 reference

12 December 2020

Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy

1 reference

12 December 2020

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

1 reference

12 December 2020

Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir

1 reference

12 December 2020

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

1 reference

12 December 2020

Indinavir induces acute and reversible peripheral insulin resistance in rats.

1 reference

12 December 2020

Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells

1 reference

12 December 2020

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

1 reference

12 December 2020

A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia

1 reference

12 December 2020

Plasma lipids in HIV-infected patients: a prospective study in 95 patients

1 reference

12 December 2020

The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B.

1 reference

12 December 2020

The effect of protease inhibitors on weight and body composition in HIV-infected patients

1 reference

12 December 2020

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

1 reference

12 December 2020

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

1 reference

12 December 2020

Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers

1 reference

12 December 2020

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study

1 reference

12 December 2020

The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes

1 reference

12 December 2020

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

12 December 2020

Increased de novo hepatic lipogenesis in human immunodeficiency virus infection

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors

1 reference

12 December 2020

Development of multiple lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatrophy

1 reference

12 December 2020

An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients

1 reference

12 December 2020

Adiponectin and HIV-lipodystrophy: taking HAART.

1 reference

12 December 2020

HIV protease inhibitors acutely impair glucose-stimulated insulin release.

1 reference

12 December 2020

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

12 December 2020

Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy

1 reference

12 December 2020

Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients

1 reference

12 December 2020

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

1 reference

12 December 2020

The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes

1 reference

12 December 2020

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

1 reference

12 December 2020

The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle

1 reference

12 December 2020

Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results

1 reference

12 December 2020

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

1 reference

12 December 2020

HIV protease inhibitors increase adiponectin levels in HIV-negative men.

1 reference

12 December 2020

Adiponectin Ameliorates Dyslipidemia Induced by the Human Immunodeficiency Virus Protease Inhibitor Ritonavir in Mice

1 reference

12 December 2020

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

1 reference

12 December 2020

Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome

1 reference

12 December 2020

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

12 December 2020

Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy

1 reference

12 December 2020

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

1 reference

12 December 2020

Hypertriglyceridemia in the acquired immunodeficiency syndrome

1 reference

12 December 2020

Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen

1 reference

12 December 2020

Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults

1 reference

12 December 2020

Severe diabetes associated with protease inhibitor therapy

1 reference

12 December 2020

Lipid evaluation in HIV-1-positive patients treated with protease inhibitors

1 reference

12 December 2020

Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study

1 reference

12 December 2020

Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men

1 reference

12 December 2020

How to measure insulin sensitivity

1 reference

12 December 2020

Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy

1 reference

12 December 2020

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations

1 reference

12 December 2020

Protease inhibitor-associated hyperglycaemia

1 reference

12 December 2020

Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens

1 reference

12 December 2020

Adipocyte-derived hormone levels in HIV lipodystrophy.

1 reference

12 December 2020

Indinavir increases glucose production in healthy HIV-negative men.

1 reference

12 December 2020

The metabolic effects of lopinavir/ritonavir in HIV-negative men

1 reference

12 December 2020

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

1 reference

12 December 2020

ApoE genotype and protease-inhibitor-associated hyperlipidaemia

1 reference

12 December 2020

Metabolic effects of indinavir in healthy HIV-seronegative men

1 reference

12 December 2020

Direct interference of HIV protease inhibitors with pancreatic beta-cell function

1 reference

12 December 2020

10.1007/S11908-004-0067-5

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15538985